Clinical Research Grants

Clinical Research Awards for Neurofibromatosis: Request for Letters of Intent

The Children’s Tumor Foundation announces a call for Letters of Intent for Clinical Research Awards of up to $100,000. Clinical Research Awards seeks broad-thinking novel ideas to conduct pilot clinical trials of candidate therapeutics for the treatment of tumors and other manifestations of NF1, NF2 and schwannomatosis; OR innovative studies ancillary or adjunct to clinical trials that - if successful - will contribute to the advancement of effective clinical therapies for neurofibromatosis.

Examples of projects encouraged may include but are not limited to:
- Biomarker studies adjunct to an ongoing clinical trial (may be e.g. molecular, imaging or genetic biomarkers, or other novel outcome parameters) that may better inform on and ultimately help accelerate a clinical trial.
- Preclinical/clinical collaborative studies (‘clinical co-trials’). Note however that all studies must include a clinical element – preclinical-only studies are not eligible.
- Applications to fund pilot neurofibromatosis clinical trials are welcomed an encouraged.

It is anticipated that CTF will fund up to four Clinical Research Awards of up to $100,000 (including overheads/indirect costs).

Application Process and Timeline
LOI’s due: September 15, 2010
Applicants notified: October 4, 2010

Successful LOIs will be invited to submit a full application.

Full applications due: November 15, 2010
Applicants notified: Mid-December 2010
Funding commences as early as: January 2011

Before submitting your LOI, you are strongly encouraged to contact me to discuss your idea.

Kim Hunter-Schaedle, Ph.D.
Chief Scientific Officer
Children's Tumor Foundation
Khunter-schaedle@ctf.org
Tel: 212-344-6633 x231

Nephrotic Syndrome Study Network (NEPTUNE) Career Development Fellowship

Deadline for application: November 2, 2010

Objectives: The NEPTUNE Career Development program is designed to support advanced post-doctoral and junior faculty trainees, or established investigators interested in redirecting their investigative focus, who are preparing to become independent investigators in clinical and translational research in human glomerular disease. Successful applicants will design and carry out an individually tailored program that combines a clearly defined training component with a mentored research experience that employs the unique resources of NEPTUNE.

• Eligibility:

o Clinical fellows (MD, MD/PhD, or equivalent degrees) who have completed their clinical training in nephrology or pathology or a subspecialty relevant to the study of glomerular disease in humans
o Advanced PhD post-doctoral fellows with training in biostatistics or translational research who seek advanced training in clinical research in human glomerular disease
o Junior faculty with training similar to that noted above who are interested in establishing a career investigating glomerular disease in humans
o Established investigators interested in refocusing their investigative path to include studies of glomerular disease in humans
o Individuals must be specifically interested in training to do translational or clinical research. Translational research can be broadly interpreted to include laboratory or in silico investigations that can be directly applied to studying human glomerular disease. Examples of these types of investigations include but are not limited to identification of molecular biomarkers, studies involving techniques of human genetics, or studies involving generation or application of the tools of biostatistical modeling and epidemiological studies.
o Applicants can come from Consortium participant institutions or elsewhere as long as trainee relocates to or is located in close physical proximity to a participant institution for training.

This training program is NOT intended for pre-doctoral candidates or junior level post-doctoral fellows.

• Training Program should have two components:

o Mentored research project with an established investigator conducting clinical or translational research in the area of or related to human glomerular disease; ideally, the trainee’s project should employ the unique infrastructure, clinical data, or specimens assembled by NEPTUNE

o Applicants are encouraged to create an individualized training program that would enhance their formal skills in clinical research design, statistics, etc. relevant to their intended investigative path. If appropriate, this might include formal class work, participation in ongoing seminar series, or other appropriate training. Consideration should be given to employing local resources to help defray the costs of this training.

• Requirements

o Applicants must devote a minimum of 50% effort to their training
o Applicant institutions must provide written commitment to protecting trainee’s time and providing financial support of the applicant

• Funding

o A maximum of $60,000 per year to support salary and fringe benefits only
o Duration of grant support will be a minimum of 1 and maximum of 2 years
o In necessary, applicant institutions are encouraged to contribute to financial and other resources necessary for the success of the proposed training program; the use of CTSA funding and other institutional resources should be considered
o Indirect Costs: no institutional overhead will be funded since this fellowship will be funded by Nephcure

The NephCure Foundation 15 Waterloo Ave Berwyn, PA 19312

1.866 NephCure (637-4287)

info@nephcure.org

Sleep Research Society Young Investigator Award

The deadline to submit nominations for all SRS Awards is Friday, September 17, 2010.

Nominations may be sent via e-mail to ncekosh@srsnet.org or they can be mailed to the Sleep Research Society, Attn: Nick Cekosh, 2510 North Frontage Road, Darien, IL 60561.

This award recognizes an outstanding research effort by a new investigator in the field of sleep research. The basis for evaluation of candidates is a single publication in a refereed journal. The candidate should be the first author; and the article must be published or officially accepted for publication by the application deadline. On the application deadline, the candidate must be within 7 years of obtaining a terminal degree. Exceptions to this criterion will be considered for those applicants who feel that extenuating circumstances warrant such consideration. A letter detailing these considerations must be included with the application.

The award consists of a plaque and a travel honorarium to be applied toward travel to the SLEEP 2011, 25th Annual Meeting of the Associated Professional Sleep Societies. The plaque will be presented at a ceremony at the APSS Annual Meeting.

To apply, candidates must submit, as a single PDF or Word Document, a single CV, documentation of the date of receipt of terminal degree and, if applicable, a letter outlining extenuating circumstances . If a paper is in press at the time of application, a copy of the written notification of the paper’s acceptance for publication must also be included. Applicants should provide the name of a senior investigator who will provide a letter of recommendation. The senior investigator does not need to be an author on the paper or abstract, but should be familiar with the candidate’s role on the research project. The candidate is responsible for ensuring that the letter of recommendation from the senior investigator arrives by the application deadline. In addition, a candidate must be a member in good standing of the SRS or must include a completed application for membership and fee with the award application. Repeat applications from unsuccessful applicants from previous years are encouraged. The Young Investigator Award can only be received once by an individual.

Candidates are welcome to apply for both the Young Investigator Award and the Trainee Travel Fellowship, but in the event the candidate receives the Young Investigator Award, she/he will receive only this award. Multiple awards may be recognized, dependent on the quality of the applications.

International Association for Dental Research Basil Bibby Young Investigator Award

Supported by Unilever

Purpose: The Cariology Group of IADR has established the above Award for the purpose of promoting the interest of young scientists and students in dental caries research and related matters, and to acknowledge excellence of the research conducted by young investigators. The Award is in honor of the founding President of the Cariology Group, Dr. Basil G. Bibby.

Eligibility: Individuals who will not have reached their 40th birthday by March 16, 2011, are eligible to apply.

Criteria: The Award will be made on the basis of general excellence in research related to cariology as demonstrated by written or published reports.

Application:

Candidates may apply directly or be nominated by a member of the Cariology Group.

Supporting documents should include:

Brief curriculum vitae.
Summary of specific scientific contributions.
List of the reports or publications on which the application is based, and if possible/applicable the web-link to each of them.
Supporting statement from a colleague or member of the Cariology Group.

All documents above should be grouped into one pdf file and e-mailed to Bennett Amaechi at amaechi@uthscsa.edu.

Award:

The winner will be decided by a four-member panel and will receive a plaque and a cash award of $500. In addition, $1100 will be provided to cover registration, travel and housing expenses for the winner to attend the 2011 General Session & Exhibition of the IADR, San Diego, Calif., USA, March 16-19, 2011. The Award will be presented at the Cariology Group business meeting during the 2011 IADR General Session in San Diego.

Nomination Deadline:

Deadline for receipt of applications is: December 1, 2010.

Applications should be sent to:

Bennett T. Amaechi
Department of Community Dentistry, MC 7917
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, Texas 78229-3900
Tel: (210) 567-3200/3185
Fax: (210) 567-4587
E-mail: amaechi@uthscsa.edu

American Society for Clinical Pharmacology and Therapeutics Leon I. Goldberg Young Investigator Award

The Leon I. Goldberg Young Investigator Award was established in 1986 to honor a young scientist for accomplishments in the field of clinical pharmacology achieved early in his/her career.

The goal of the Leon I. Goldberg Young Investigator Award is to encourage and recognize young scientists active in the field of clinical pharmacology.

Eligibility
There are no restrictions concerning the scientific field in which nominees have earned their doctoral degrees. Nominees must be no more than 41 years of age as of March 1 of the year in which the award is presented. Although it is encouraged, a nominee need not be a member of the Society.

Prize and Presentation
The Leon I. Goldberg Young Investigator Award is presented at the ASCPT Annual Meeting. The recipient will deliver a lecture on his/her work. In addition, the recipient of the award will receive a plaque and a $1,000 honorarium. Travel expenses, hotel expenses and meeting registration are reimbursed by the Society.

Each year, the American Society for Clinical Pharmacology and Therapeutics Scientific Awards Program seeks to recognize outstanding science in clinical pharmacology. ASCPT Awards span the continuum of clinical pharmacology and recognize every turning point in the career path from young investigator to seasoned scientist.

The deadline to submit a nomination is September 24, 2010 at 4:00pm ET.

We encourage all members to participate in this important process. If you have any questions about any of the awards or nomination procedures, please contact meetings@ascpt.org.

ASCPT
528 N Washington St
Alexandria, VA 22314

Ph: 703.836.6981
info@ascpt.org

Gary Neil Prize for Innovation in Drug Development

The Gary Neil Prize for Innovation in Drug Development was established in 2004 to honor the memory of Gary Neil, Ph.D. Dr. Neil, a former leader of worldwide Research and Development at Wyeth-Ayerst, was a pioneer in the field of drug development. Dr. Neil was instrumental in creating a highly effective drug development and strategic decision-making structure at Alza through his roles as CEO and President of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals Corporation. Dr. Neil had a significant role as a member of the boards of directors of Pharsight Corporation, Geron Corporation, Calydon and several other biotech companies.

The goal of the Gary Neil Prize for Innovation in Drug Development is to stimulate the application of innovative science to clinical drug development by recognizing outstanding individuals or teams who have been leaders in this area.

Eligibility
Individuals as well as teams who have demonstrated leadership in the application of significant, innovative science to clinical drug development. The award is open to individuals from all clinical pharmacology employment sectors.

Prize and Presentation
The Gary Neil Prize for Innovation in Drug Development will be presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $2,500 honorarium. Travel expenses, hotel expenses and meeting registration will be reimbursed by the Society.

Each year, the American Society for Clinical Pharmacology and Therapeutics Scientific Awards Program seeks to recognize outstanding science in clinical pharmacology. ASCPT Awards span the continuum of clinical pharmacology and recognize every turning point in the career path from young investigator to seasoned scientist.

The deadline to submit a nomination is September 24, 2010 at 4:00pm ET.

We encourage all members to participate in this important process. If you have any questions about any of the awards or nomination procedures, please contact meetings@ascpt.org.

ASCPT
528 N Washington St
Alexandria, VA 22314

Ph: 703.836.6981
info@ascpt.org

Rawls-Palmer Progress in Medicine Award

The Rawls-Palmer Progress in Medicine Award was established in 1978 by Dr. W. B. Rawls to further his commitment to continuing medical education and its impact on patient care.

The goal of the Rawls-Palmer Progress in Medicine Award is to incorporate the efforts of modern research in patient care and to help bridge the gap between the results of research and its application in patient care.

Eligibility
The candidate must be an investigator who is actively involved in high-quality clinical pharmacologic research and capable of delivering an engaging, comprehensive lecture on recent developments in clinical pharmacology and therapeutics.

Prize and Presentation
The Rawls-Palmer Progress in Medicine Award is presented at the ASCPT Annual Meeting. The recipient will present a lecture focusing on recent developments in clinical pharmacology. In addition, the recipient will receive a $1,000 honorarium and a plaque. Travel expenses, hotel expenses and meeting registration will be reimbursed by the Society. This award was founded through the generosity of the late Dr. and Mrs. W.B. Rawls, and honors the memory of their parents.

Each year, the American Society for Clinical Pharmacology and Therapeutics Scientific Awards Program seeks to recognize outstanding science in clinical pharmacology. ASCPT Awards span the continuum of clinical pharmacology and recognize every turning point in the career path from young investigator to seasoned scientist.

The deadline to submit a nomination is September 24, 2010 at 4:00pm ET.

We encourage all members to participate in this important process. If you have any questions about any of the awards or nomination procedures, please contact meetings@ascpt.org.

ASCPT
528 N Washington St
Alexandria, VA 22314

Ph: 703.836.6981
info@ascpt.org

Oscar B. Hunter Memorial Award in Therapeutics

The Oscar B. Hunter Memorial Award in Therapeutics was established in 1955 to honor individual scientists for outstanding contributions to clinical pharmacology and therapeutics. This award recognizes a meritorious career in drug research, excellence or contributions in direct patient care, and a distinguished teaching career.

The Oscar B. Hunter Memorial Award in Therapeutics is the Society's premier award. The goal of the award is to honor a scientist for outstanding contributions to clinical pharmacology and therapeutics over the individual's professional life.

Eligibility
A nominee must be able to provide evidence of an exemplary career in drug research, significant contributions to excellence in patient care, and a distinguished teaching career.

Prize and Presentation
The Oscar B. Hunter Memorial Award in Therapeutics is presented at the ASCPT Annual Meeting. The recipient will present a lecture summarizing the works that form the basis of the award. In addition, the recipient of the award will receive a bronze medal mounted on a plaque and a $1,500 honorarium. Travel expenses, hotel expenses and meeting registration will be reimbursed by the Society.

Each year, the American Society for Clinical Pharmacology and Therapeutics Scientific Awards Program seeks to recognize outstanding science in clinical pharmacology. ASCPT Awards span the continuum of clinical pharmacology and recognize every turning point in the career path from young investigator to seasoned scientist.

The deadline to submit a nomination is September 24, 2010 at 4:00pm ET.

We encourage all members to participate in this important process. If you have any questions about any of the awards or nomination procedures, please contact meetings@ascpt.org.

ASCPT
528 N Washington St
Alexandria, VA 22314

Ph: 703.836.6981
info@ascpt.org

National Parkinson Foundation 2011 Request for Applications

Individual grants will be limited to a maximum of $250,000 over a period of up to two years.

NPF is pleased to issue its yearly Request for Applications (“RFA”) with the goal of funding clinical investigations in several specific areas of Parkinson’s disease research led at NPF Centers of Excellence (“COE”) and Care Consortium Centers. This RFA will provide support for well-designed clinical research that addresses comparative effectiveness of treatment, current unmet needs, and/or clinical controversies. This RFA will fund programs based on scientific merit, as determined by the NPF’s Clinical and Scientific Advisory Board (“CSAB”) in a peer-review process.

Applications will be accepted from any principal investigator affiliated with a currently certified NPF COE or a member of the NPF Care Consortium (“Applicant” from an “Eligible Institution”). Investigators not from Eligible Institutions are invited to participate as collaborators. Total grant funding is dependent upon quality of applications.

The following are the key dates for this RFA:

Release date: August 12, 2010
Application deadline: December 10, 2010 at 6:00 p.m. EST
Anticipated award announcement: On or before April 15, 2011

NATIONAL PARKINSON FOUNDATION, INC.
1501 N.W. 9th Avenue / Bob Hope Road
Miami, Florida 33136-1494
Telephone: (305)243-6666
Toll Free National: 1-800-327-4545
Fax: (305)243-6073
E-mail inquiries: contact@parkinson.org

National Psoriasis Foundation Discovery Research Grant

The National Psoriasis Foundation is seeking grant applications that encourage the advancement of innovative research in psoriasis and psoriatic arthritis. Discovery Research Grants are intended to allow researchers to undertake preliminary and proof of concept studies with the goal of developing competitive grant proposals that lead to long-term funding from the National Institutes of Health or other federal agencies.

Research pathways:
The National Psoriasis Foundation supports basic and clinical research that leads to the prevention, diagnosis and cure of psoriasis and psoriatic arthritis. Priority consideration will be given to applications that address one or more of the Foundation’s research pathways: (1) genetics, (2) cell biology, (3) immunology, and (4) epidemiological/health services research.

Anticipated number of awards:
It is anticipated that as many as nine new Discovery Research Grants will be awarded in 2011. Awards are contingent on the availability of funds and the receipt of sufficiently meritorious applications.

Budget and Project period:
Applicants may request up to $50,000 (direct costs only) per year. The total project period for the application submitted in response to this RFP is one year.

Research plan length:
The research proposal cannot exceed five (5) pages including figures and tables, excluding references.

Eligibility:
It is expected that the principal investigator will be personally and actively responsible for the conduct of the research and is considered eligible by his or her institution to apply for a research grant. The principal investigator need not be a United States citizen.

Important deadlines:
The application must be received by Monday October 4th, 2010. The applications will be evaluated by an expert panel of peer reviewers and awards will be made no later than March 1, 2011.

Application:
Completed applications should be converted to a single PDF file and submitted by email to: research@psoriasis.org.

Questions:
For more information on the Discovery Research Grant program please contact the Director of Research, Bruce F. Bebo, Jr., PhD. Phone: 503-546-8404; E-mail: research@psoriasis.org.